한일의료기

비상장계속사업자

Hanil Medical.,Ltd

배철식

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

한일의료기

Business Reg. No. 1418118834 · CEO 배철식

I.Investment Overview

Target한일의료기 (1418118834)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명한일의료기
영문명Hanil Medical.,Ltd
대표자배철식
사업자등록번호1418118834
법인등록번호2849110085463
설립일2010.04.01
종업원수43명

V.Workforce

43

Current headcount · 2026.07 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW233.82021262.72022318.12023347.92024377.52025
영업이익100M KRW25.9202141.3202237.4202333.9202441.92025
순이익100M KRW18.6202130.1202222.3202320.3202433.32025
Item20252024202320222021
자산총계241.2억원207.6억원190.3억원177.3억원131.7억원
부채총계97억원96.8억원99.8억원91.5억원67억원
자본총계144.1억원110.8억원90.5억원85.8억원64.7억원
매출액377.5억원347.9억원318.1억원262.7억원233.8억원
영업이익41.9억원33.9억원37.4억원41.3억원25.9억원
순이익33.3억원20.3억원22.3억원30.1억원18.6억원

VII.Financial Ratios

FY2025 basis

11.09%

영업이익률

8.83%

순이익률

13.82%

ROA

23.12%

ROE

67.33%

부채비율

59.76%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

한일의료기 투심보고서 | Alpha Lenz